Cargando…

Viral and bacterial vectors of immunogenes()

A recent development in the production of experimental vaccines has been the use of the smallpox vaccine virus (vaccinia virus) as a carrier (vector) of the genes (immunogenes) which code for the protection-inducing proteins (immunogens) of unrelated viruses. The potential of these vector vaccines l...

Descripción completa

Detalles Bibliográficos
Autor principal: Cavanagh, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 1985
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131544/
https://www.ncbi.nlm.nih.gov/pubmed/4002835
http://dx.doi.org/10.1016/0264-410X(85)90011-8
_version_ 1783517262814117888
author Cavanagh, David
author_facet Cavanagh, David
author_sort Cavanagh, David
collection PubMed
description A recent development in the production of experimental vaccines has been the use of the smallpox vaccine virus (vaccinia virus) as a carrier (vector) of the genes (immunogenes) which code for the protection-inducing proteins (immunogens) of unrelated viruses. The potential of these vector vaccines lies in the hope that such a vaccine would be cheaper, safer and/or more effective than existing vaccines to some pathogens. Vaccinia virus as a vector has attracted most attention to date because: (a) several immunogenes can be inserted into its genome without destroying its infectivity; (b) the immunogens appear to be produced normally; (c) vaccinia virus has been used highly successfully to eradicate smallpox; and (d) it has a wide host-range and thus might find veterinary as well as human medical application. Experimental vaccines, successfully tested in animals, have been prepared using immunogenes from influenza virus, hepatitis B virus and herpes simplex virus. Apathogenic enteric bacteria have some potential as vectors, most probably against enteric pathogens, although the potential of viral vectors is likely to be realized first. Parasitic worms and protozoa devastate millions of people. When the immunogens of these organisms have been identified there will be added impetus to investigate the potential of vector vaccines against these pathogens.
format Online
Article
Text
id pubmed-7131544
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71315442020-04-08 Viral and bacterial vectors of immunogenes() Cavanagh, David Vaccine Article A recent development in the production of experimental vaccines has been the use of the smallpox vaccine virus (vaccinia virus) as a carrier (vector) of the genes (immunogenes) which code for the protection-inducing proteins (immunogens) of unrelated viruses. The potential of these vector vaccines lies in the hope that such a vaccine would be cheaper, safer and/or more effective than existing vaccines to some pathogens. Vaccinia virus as a vector has attracted most attention to date because: (a) several immunogenes can be inserted into its genome without destroying its infectivity; (b) the immunogens appear to be produced normally; (c) vaccinia virus has been used highly successfully to eradicate smallpox; and (d) it has a wide host-range and thus might find veterinary as well as human medical application. Experimental vaccines, successfully tested in animals, have been prepared using immunogenes from influenza virus, hepatitis B virus and herpes simplex virus. Apathogenic enteric bacteria have some potential as vectors, most probably against enteric pathogens, although the potential of viral vectors is likely to be realized first. Parasitic worms and protozoa devastate millions of people. When the immunogens of these organisms have been identified there will be added impetus to investigate the potential of vector vaccines against these pathogens. Published by Elsevier Ltd. 1985-03 2002-11-13 /pmc/articles/PMC7131544/ /pubmed/4002835 http://dx.doi.org/10.1016/0264-410X(85)90011-8 Text en © 1985 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cavanagh, David
Viral and bacterial vectors of immunogenes()
title Viral and bacterial vectors of immunogenes()
title_full Viral and bacterial vectors of immunogenes()
title_fullStr Viral and bacterial vectors of immunogenes()
title_full_unstemmed Viral and bacterial vectors of immunogenes()
title_short Viral and bacterial vectors of immunogenes()
title_sort viral and bacterial vectors of immunogenes()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131544/
https://www.ncbi.nlm.nih.gov/pubmed/4002835
http://dx.doi.org/10.1016/0264-410X(85)90011-8
work_keys_str_mv AT cavanaghdavid viralandbacterialvectorsofimmunogenes